STUDY DESIGN VESALIUS-CV was a randomized, double-blind, placebo-controlled, multicenter trial conducted across 33 countries that enrolled 12,257 patients to evaluate the impact of evolocumab on major adverse cardiovascular events (MACE) in patients at high cardiovascular (CV) risk without prior my

The Ez-PAVE trial showed that intensive LDL-C targeting <55mg/dL significantly reduced 3-year composite cardiovascular events compared with conventional targeting <70mg/dL in patients with ASCVD, without increasing major safety concerns, supporting a more aggressive LDL-C control in line with current guidelines.

Since the release of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines on managing dyslipidemias to lower cardiovascular (CV) risk, several randomized controlled trials have emerged that could influence patient management prior to the next comprehensive

STUDY DESIGN Lerodalcibep is a third-generation proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor that prevents PCSK9 from binding to low-density lipoprotein receptors (LDLRs).1 Low-density lipoprotein-cholesterol (LDL-C) clearance from the bloodstream is enhanced as a result of LDLR

A reduction in LDL-C is associated with improvements in CV outcomes in patients with ASCVD.¹ As such, multiple guidelines recommend LDL-C targets of <55mg/dL and <70mg/dL based on baseline risks.¹ However, many patients fail their LDL-C goals due to clinical inertia, medication nonadherence, side effects, and/or poor healthcare access.¹ Inclisiran is a first-in-class siRNA that inhibits hepatic PCSK9 production and increases LDL receptor expression and LDL-C clearance.¹ In clinical studies, twice-yearly administration of inclisiran has been shown to achieve a 50% reduction in LDL-C.¹

STUDY DESIGN Dual antiplatelet therapy (DAPT) with aspirin + a potent P2Y12 receptor inhibitor for 12 months is the mainstay for patients presenting with acute coronary syndrome (ACS) who have been treated with percutaneous coronary intervention (PCI) to prevent myocardial infarction (MI) and stent

Acute coronary syndromes (ACS) encompass a spectrum of conditions including unstable angina, non-ST-elevation myocardial  infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI).¹ Although patients may present differently with ACS, they face many similar diagnostic tests, invasive management

Mixed data have been observed on the role of statins in the preventative setting of cardiovascular disease (CVD).¹ However, Dr. Raffaele Bugiardini, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy and his colleagues conducted a recent study published in the Journal of the American College of Cardiology, which demonstrated evidence that receiving statin therapy before initial acute coronary syndrome (ACS) could reduce acute heart failure (AHF) and improve patient survival rates.²